Head-To-Head Review: Iradimed (NASDAQ:IRMD) and Daxor (NASDAQ:DXR)

Iradimed (NASDAQ:IRMD) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Dividends

Iradimed pays an annual dividend of $0.60 per share and has a dividend yield of 1.3%. Daxor pays an annual dividend of $0.03 per share and has a dividend yield of 0.4%. Iradimed pays out 42.6% of its earnings in the form of a dividend.

Risk & Volatility

Iradimed has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Iradimed and Daxor, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iradimed	0	0	3	0	3.00
Daxor	0	0	0	0	N/A

Iradimed currently has a consensus price target of $60.00, suggesting a potential upside of 30.89%. Given Iradimed’s higher probable upside, equities analysts clearly believe Iradimed is more favorable than Daxor.

Valuation and Earnings

This table compares Iradimed and Daxor’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iradimed	$69.48 million	8.35	$17.19 million	$1.41	32.51
Daxor	$1.28 million	31.37	N/A	N/A	N/A

Iradimed has higher revenue and earnings than Daxor.

Insider and Institutional Ownership

92.3% of Iradimed shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 42.6% of Iradimed shares are owned by insiders. Comparatively, 59.0% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Iradimed and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iradimed	26.83%	25.18%	20.90%
Daxor	N/A	N/A	N/A

Summary

Iradimed beats Daxor on 9 of the 12 factors compared between the two stocks.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.